Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by  Zacks Research  from a “buy” ranking to a “hold” ranking in a research note provided to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm. It focuses on discovering and establishing little particle medication candidates to treat cancer. The Firm‘s products under different stages of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several various other equities research experts also lately talked about the company. Noble Financial editioned a “get” score as well as released a $11.00 rate goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and established a “acquire” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating average rate of $2.90 as well as a two-hundred day moving ordinary rate of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) profits per share for the quarter, topping analysts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as a negative internet margin of 8,294.27%. The firm had income of $0.06 million throughout the quarter, compared to the agreement quote of $0.06 million. Throughout the exact same quarter in the prior year, the company uploaded ($ 0.45) EPS. En masse, research experts anticipate that Onconova Therapeutics will certainly post -1.18 EPS for the present year.

A variety of hedge funds have actually just recently dealt shares of ONTX. GSA Capital Partners LLP got a brand-new position in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Resources Monitoring LP got a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC got a new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC acquired a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP got a brand-new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and other institutional investors possess 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the identification and growth of oncology therapeutics. It focuses on uncovering and creating tiny molecule medication prospects to deal with cancer cells. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For additional information concerning research offerings from Zacks Investment Research, check out Zacks.com.

This instant information alert was generated by narrative science innovation and also financial information from Market in order to supply visitors with the fastest and also most accurate coverage. This story was evaluated by Market’s content team prior to publication. 



Before you think about Onconova Therapeutics, you’ll intend to hear this.

Market monitors Wall Street’s top-rated and best doing research experts as well as the stocks they suggest to their clients daily. Market has determined the 5 stocks that cover analysts are quietly murmuring to their customers to acquire now prior to the more comprehensive market catches on … and Onconova Therapeutics wasn’t on the listing.

While Onconova Therapeutics currently has a “Buy” ranking among experts, top-rated analysts think these 5 stocks are better acquires.

You may also like